BAM
DNLI icon

Belpointe Asset Management’s Denali Therapeutics DNLI Stock Holding History

Belpointe Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-374
Closed -$8.62K – 1271
2023
Q1 		$8.62K Hold
374
– – ﹤0.01% 2793
2022
Q4 		$10.4K Buy
+374
New +$11.1K ﹤0.01% 2597

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Belpointe Asset Management's DNLI Position: Q2 2023 in Review

Belpointe Asset Management sold out of Denali Therapeutics (DNLI) in Q2 2023, closing a stake of 374 shares — an estimated $8.62K sold.

Belpointe Asset Management first reported a position in DNLI in Q4 2022 and held it in 2 quarters. The position peaked at $10.4K in Q4 2022. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2023.

  • Belpointe Asset Management reported no remaining Denali Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 374 Denali Therapeutics shares in Q2 2023, an estimated $8.62K.
  • Belpointe Asset Management first reported a position in Denali Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Denali Therapeutics position peaked at $10.4K in Q4 2022.
  • 203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.